Evidence map›Paper›PMID 32295417›Full record

Trial reportCirculation. Cardiovascular interventions2020

Effects of Acute Colchicine Administration Prior to Percutaneous Coronary Intervention: COLCHICINE-PCI Randomized Trial.

Binita Shah, Michael Pillinger, Hua Zhong, Bruce Cronstein, Yuhe Xia, Jeffrey D Lorin, Nathaniel R Smilowitz, Frederick Feit, Nicole Ratnapala, Norma M Keller and 1 more

3 registry-linked trialsOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation. Cardiovascular interventions, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 89 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 14 pooled it
9.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01709981 phase4completednot on this map

Anti-inflammatory Effects of Colchicine in Patients Undergoing Percutaneous Coronary Intervention: Inflammatory Marker Substudy of the Colchicine-PCI Trial

TypeinterventionalSponsorNYU Langone HealthRan2013 to 2021Enrolled280ConditionsCoronary Artery DiseaseArmsColchicine, Placebo
NCT02594111 phase4completednot on this map

Anti-inflammatory Therapy During Percutaneous Coronary Intervention

TypeinterventionalSponsorVA Office of Research and DevelopmentRan2013 to 2021Enrolled714ConditionsCoronary Artery Disease, Acute Coronary SyndromeArmsColchicine vs Placebo
NCT05739929 phase3unknown statusnot on this mapstarted 2023, after this paper: background citation

Colchicine Protective Effect in Patients Undergoing Elective Percutaneous Coronary Intervention (COLCHICINE-PROTECT) A Randomized, Placebo-controlled, Double-blind Clinical Trial

TypeinterventionalSponsorHelwan UniversityRan2023 to 2024Enrolled400ConditionsCoronary Artery DiseaseArmsColchicine 0.5 MG Oral Tablet, Placebo
3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 14 syntheses or guidelines pooled it, 175 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Efficacy of Colchicine for Prevention of Stroke and Adverse Cardiovascular Events: A Meta-analysis of 16 Randomized Controlled Trials.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Safety and Efficacy of Colchicine in Patients with Stable CAD and ACS: A Systematic Review and Meta-analysis.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2021
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Review
  20. Review

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Binita ShahSection of Cardiology, Department of Medicine (B.S., J.D.L., N.R.S.), VA New York Harbor Health Care System.
Michael PillingerSection of Rheumatology, Department of Medicine (M.P.), VA New York Harbor Health Care System.
Hua ZhongDivision of Biostatistics, Department of Population Health (H.Z., Y.X.), New York University School of Medicine.
Bruce CronsteinDivision of Rheumatology, Department of Medicine (M.P., B.C.), New York University School of Medicine.
Yuhe XiaDivision of Biostatistics, Department of Population Health (H.Z., Y.X.), New York University School of Medicine.
Jeffrey D LorinSection of Cardiology, Department of Medicine (B.S., J.D.L., N.R.S.), VA New York Harbor Health Care System.
Nathaniel R SmilowitzSection of Cardiology, Department of Medicine (B.S., J.D.L., N.R.S.), VA New York Harbor Health Care System.
Frederick FeitDivision of Cardiology, Department of Medicine (B.S., J.D.L., N.R.S., F.F., N.R., N.M.K., S.D.K.), New York University School of Medicine.
Nicole RatnapalaDivision of Cardiology, Department of Medicine (B.S., J.D.L., N.R.S., F.F., N.R., N.M.K., S.D.K.), New York University School of Medicine.
Norma M KellerDivision of Cardiology, Department of Medicine (B.S., J.D.L., N.R.S., F.F., N.R., N.M.K., S.D.K.), New York University School of Medicine.
Stuart D KatzDivision of Cardiology, Department of Medicine (B.S., J.D.L., N.R.S., F.F., N.R., N.M.K., S.D.K.), New York University School of Medicine.
Norwegian Womens Public Health Association · NOVA NY Harbor Healthcare System · USNew York University · US

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1M
Anti-inflammatory therapy during percutaneous coronary interventionIK2CX001074 · VA · VA MEDICAL CENTER · PI SHAH, BINITA · 2016 to 2021
–
CSRD VA IK2 CX001074NCI NIH HHS P30 CA016087
6 · The paper itself

Abstract

backgroundVascular injury and inflammation during percutaneous coronary intervention (PCI) are associated with increased risk of post-PCI adverse outcomes. Colchicine decreases neutrophil recruitment to sites of vascular injury. The anti-inflammatory effects of acute colchicine administration before PCI on subsequent myocardial injury are unknown.

methodsIn a prospective, single-site trial, subjects referred for possible PCI (n=714) were randomized to acute preprocedural oral administration of colchicine 1.8 mg or placebo.

resultsAmong the 400 subjects who underwent PCI, the primary outcome of PCI-related myocardial injury did not differ between colchicine (n=206) and placebo (n=194) groups (57.3% versus 64.2%,

conclusionsAcute preprocedural administration of colchicine attenuated the increase in interleukin-6 and high-sensitivity C-reactive protein concentrations after PCI when compared with placebo but did not lower the risk of PCI-related myocardial injury. Registration: URL: https://www.clinicaltrials.gov; Unique Identifiers: NCT02594111, NCT01709981.

Indexed as

Acute Coronary SyndromeAdministration, OralAgedAnti-Inflammatory AgentsBiomarkersColchicineCoronary Artery DiseaseC-Reactive ProteinDouble-Blind MethodDrug Administration ScheduleFemaleHumansInflammationInflammation MediatorsInterleukin-6MaleAnti-Inflammatory AgentsBiomarkersColchicineC-Reactive ProteinIL6 protein, humanInflammation MediatorsInterleukin-6biomarkercolchicineinflammationmyocardial infarctionpercutaneous coronary intervention

Identifiers

PMID32295417
PMCPMC7169992
OpenAlexW3016436366

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.